Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.25 | 0.31 | -0.16 |
| FCF Yield | -30.05% | -16.13% | -21.75% | -11.11% |
| EV / EBITDA | -3.73 | -5.41 | -5.16 | -5.87 |
| Quality | ||||
| ROIC | -79.25% | -52.85% | -59.16% | -40.51% |
| Gross Margin | 34.98% | 61.03% | 69.91% | 68.88% |
| Cash Conversion Ratio | 0.67 | 0.54 | 0.79 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.36% | 105.28% | 473.24% | 60.18% |
| Free Cash Flow Growth | -3.19% | 9.62% | -31.14% | -67.02% |
| Safety | ||||
| Net Debt / EBITDA | -1.17 | -1.01 | -0.84 | 0.47 |
| Interest Coverage | -16.37 | -16.52 | -43.79 | -18.03 |
| Efficiency | ||||
| Inventory Turnover | 3.34 | 2.82 | 2.31 | 0.81 |
| Cash Conversion Cycle | 119.37 | 128.56 | 8.71 | -475.43 |